STOCK TITAN

Fate Therapeutics, Inc. - FATE STOCK NEWS

Welcome to our dedicated page for Fate Therapeutics news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutics stock.

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's innovative approach leverages induced pluripotent stem cell (iPSC) technology to create off-the-shelf, engineered NK- and T-cell product candidates designed to deliver multiple therapeutic mechanisms to patients.

Fate Therapeutics' proprietary iPSC product platform enables the mass production of multiplexed-engineered cell products that are uniform in composition and can be stored for off-the-shelf availability. This platform allows for the efficient manufacture of well-defined cell therapies that can be used in combination with other treatments, significantly overcoming the limitations of patient- or donor-sourced cells.

Recent highlights include the initiation of patient enrollment in the Phase 1 study of FT522, an ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma. Additionally, the FDA has cleared the IND application for FT825/ONO-8250 in solid tumors, marking a key milestone in the company's collaboration with ONO Pharmaceutical. The expansion of the iPSC product platform into autoimmunity with FT819, targeting systemic lupus erythematosus, further underscores Fate Therapeutics' commitment to addressing complex diseases.

The company's financial health remains robust, bolstered by recent funding efforts, including the sale of shares and pre-funded warrants to institutional investors. Fate Therapeutics continues to lead in the field of cellular immunotherapies, with a strong pipeline of product candidates and an intellectual property portfolio comprising over 500 issued patents and 500 pending patent applications.

Headquartered in San Diego, CA, Fate Therapeutics is dedicated to advancing its clinical programs and providing innovative treatments to improve patient outcomes. For more information, please visit www.fatetherapeutics.com.

Rhea-AI Summary

Fate Therapeutics announced a collaboration with ONO Pharmaceutical to develop the FT825/ONO-8250 CAR T-cell product candidate targeting HER2-expressing solid tumors. ONO has exercised its option to FT825/ONO-8250, enabling joint commercialization in the U.S. and Europe, while ONO holds exclusive rights in the rest of the world. Fate will receive milestone payments and is set to initiate IND-enabling activities aiming for an FDA IND application in 2023. Preclinical data suggest FT825/ONO-8250 has a unique therapeutic profile, overcoming challenges in solid tumor treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced its participation in several upcoming investor conferences. The key events include Cowen’s 6th Annual IO Next Summit on November 11, 2022, Jefferies London Healthcare Conference on November 16, 2022, and Piper Sandler 34th Annual Healthcare Conference on November 29, 2022. Presentations will be available via live webcasts on the Company’s website, with archived recordings shortly after the events. Fate Therapeutics focuses on developing innovative cellular immunotherapies for cancer patients using its proprietary iPSC platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
Rhea-AI Summary

Fate Therapeutics reported on November 3, 2022, positive FDA feedback for its FT516 program under RMAT designation, supporting its iPSC product platform for aggressive lymphomas. The company is conducting multiple Phase 1 studies, including FT596 for r/r B-cell lymphoma and FT576 for multiple myeloma. The third quarter of 2022 saw total revenue of $15 million against R&D expenses of $79.8 million, reflecting significant investment in product development. Cash and investments totaled $519.1 million, providing a solid financial foundation for ongoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
Rhea-AI Summary

Fate Therapeutics announced that fourteen presentations have been accepted for the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. Key highlights include initial Phase 1 clinical data for the FT576 CAR NK cell targeting BCMA and FT819 CAR T-cell targeting CD19. The company will also present preclinical data for FT555 and discuss innovative methods to enhance the efficacy of off-the-shelf iPSC-derived cell therapies, such as eliminating patient conditioning. The ASH presentations aim to showcase advancements in Fate's iPSC product platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences clinical trial
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced a conference call and live audio webcast scheduled for November 3, 2022 at 5:00 PM ET to discuss its third quarter 2022 financial results and provide a corporate update. This event reflects the company's ongoing commitment to transparency with its investors. The call will be accessible via registration, and an archived version will be available on the company's website shortly after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
conferences earnings
-
Rhea-AI Summary

Fate Therapeutics, Inc. (NASDAQ: FATE) has announced its participation in the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, scheduled for November 8-12, 2022. The company will present clinical and preclinical data on its induced pluripotent stem cell (iPSC) product platform, including interim Phase I results of FT538, FT516, and FT500 therapies targeting advanced solid tumors. These presentations aim to demonstrate the efficacy of engineered cell therapies designed to enhance treatment outcomes for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences clinical trial
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced its participation in several investor conferences in September 2022. The company will host 1x1 meetings at Citi’s 17th Annual BioPharma Conference on September 8, and participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on September 9 and the Morgan Stanley 20th Annual Global Healthcare Conference on September 12. Fate will also join fireside chats at the Baird 2022 Global Health Conference and H.C. Wainwright 24th Annual Global Investment Conference on September 13. Webcasts will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) has announced significant progress in its clinical research with the publication of preclinical study results on TCR-CAR+ iPSC-derived CD8αβ T cells, demonstrating robust anti-tumor responses in systemic leukemia models. These findings support the ongoing Phase 1 study of FT819, a first-of-its-kind iPSC-derived T-cell therapy, aimed at treating relapsed/refractory B-cell malignancies. The research, conducted with Memorial Sloan Kettering Cancer Center, highlights the potential for off-the-shelf cancer immunotherapies that overcome manufacturing challenges associated with traditional therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
-
Rhea-AI Summary

Fate Therapeutics reported its Q2 2022 results, highlighting ongoing clinical trials for its product candidates targeting aggressive B-cell lymphoma and solid tumors. The company has initiated enrollment in multiple studies, including FT596+R for relapsed/refractory B-cell lymphoma and FT536 for solid tumors. With $580.8 million in cash and $18.5 million in revenue for the quarter, Fate is actively expanding collaborations with Janssen and ONO. R&D expenses totaled $81.3 million, reflecting investment in its innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced a conference call on August 3, 2022, at 5:00 PM ET to discuss its Q2 2022 financial results and provide a corporate update. The call can be accessed via phone or a live audio webcast available on the Company’s website. Fate Therapeutics focuses on developing advanced cellular immunotherapies for cancer patients, utilizing its proprietary induced pluripotent stem cell (iPSC) technology. The Company aims to establish a leadership position in the clinical development of universal, off-the-shelf cell products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences earnings

FAQ

What is the current stock price of Fate Therapeutics (FATE)?

The current stock price of Fate Therapeutics (FATE) is $1.66 as of December 23, 2024.

What is the market cap of Fate Therapeutics (FATE)?

The market cap of Fate Therapeutics (FATE) is approximately 181.7M.

What does Fate Therapeutics specialize in?

Fate Therapeutics specializes in the development of programmed cellular immunotherapies for cancer and autoimmune disorders using induced pluripotent stem cell (iPSC) technology.

What is the iPSC product platform?

The iPSC product platform is a proprietary technology that allows Fate Therapeutics to mass-produce multiplexed-engineered cell products that are uniform in composition and can be stored for off-the-shelf availability.

What are the recent achievements of Fate Therapeutics?

Recent achievements include the initiation of Phase 1 studies for FT522 in B-cell lymphoma and the FDA clearance of the IND application for FT825/ONO-8250 in solid tumors. The company also expanded its iPSC platform into autoimmunity with FT819 for systemic lupus erythematosus.

What is the financial condition of Fate Therapeutics?

Fate Therapeutics is financially robust, supported by recent funding through the sale of shares and pre-funded warrants to institutional investors, which are expected to generate approximately $100 million in gross proceeds.

Where is Fate Therapeutics headquartered?

Fate Therapeutics is headquartered in San Diego, California.

How does Fate Therapeutics address the limitations of patient- or donor-sourced cells?

Fate Therapeutics uses its iPSC product platform to produce well-defined, uniform cell therapies that can be stored off-the-shelf, overcoming the limitations associated with patient- or donor-sourced cells.

What is the significance of FT522 and FT825/ONO-8250?

FT522 is an ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma, and FT825/ONO-8250 is an iPSC-derived CAR T-cell program for solid tumors. Both represent significant advancements in Fate Therapeutics' clinical pipeline.

What diseases does Fate Therapeutics aim to treat?

Fate Therapeutics develops treatments for a range of diseases, including cancer, autoimmune disorders, hematological diseases, traumatic injuries, and degenerative diseases.

What makes Fate Therapeutics' iPSC product platform unique?

The iPSC product platform is unique due to its ability to mass-produce multiplexed-engineered cell products that are well-defined, uniform, and can be stored for off-the-shelf availability, making them readily accessible for patients.

How can I learn more about Fate Therapeutics?

For more information, you can visit Fate Therapeutics' official website at www.fatetherapeutics.com.

Fate Therapeutics, Inc.

Nasdaq:FATE

FATE Rankings

FATE Stock Data

181.66M
109.39M
2.17%
102.7%
9.12%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO